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The WW and C2 domain containing 1 (WWC1) gene encodes a protein
named WWC1 (or KIBRA), which is involved in the Hippo signaling path-
way. WWC1 is often lost in triple-negative breast cancer and has been
shown to suppress tumor metastasis. In this study, 470 breast cancer
patients were recruited and WWC1 expression in the tumor samples was
measured with quantitative reverse transcriptase PCR. Associations of
WWC1 expression with breast cancer survival were analyzed using the Cox
proportional hazards regression model and Kaplan–Meier survival analysis.
The relationship between WWC1 expression and methylation was evalu-
ated in a dataset from The Cancer Genome Atlas. Using our microarray
data on gene expression and the Ingenuity Pathway Analysis, we predicted
the WWC1-associated signaling pathways in breast cancer. Our results
showed that low expression of WWC1 was significantly associated with
advanced-stage diseases, high-grade tumors, and estrogen receptor- or pro-
gesterone receptor-negative status. Compared to those with high expres-
sion, patients with low WWC1 had higher risk of breast cancer relapse
[hazard ratio (HR) = 2.06, 95% confidence interval (CI): 1.26–3.37] and
higher risk of death (HR = 2.76, 95% CI: 1.51–5.03). The association with
relapse-free survival remained significant after adjustment for disease stage,
tumor grade, and hormone receptor status and was replicated in a public
dataset. Analysis of high-throughput gene expression data indicated that
WWC1 was involved in the Hippo signaling pathway. Online data also
suggested that DNA methylation was inversely associated with WWC1
expression. The study confirmed that low WWC1 expression was associated
with aggressive breast cancer and poor survival outcomes.
Breast cancer is the most common malignancy and a
leading cause of cancer death among women world-
wide. The malignancy accounts for 25% of all
cancer cases and 15% of all cancer deaths. In devel-
oped countries, these figures are even higher, about
50% of all cancer cases and 38% of cancer deaths
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[2]. Breast cancer is a heterogeneous disease [2], and
accurately characterizing breast tumor at molecular
and genetic levels is important in identifying sensitive
and responsive targets for treatment. Triple-negative
breast cancer (TNBC) is a group of aggressive
tumors with poor prognosis. Nearly 70% of TNBC
had a deletion in chromosome 5 (5q11–5q35) [3–5].
A recent study by Knight et al. indicated that a
gene in the region named the WW and C2 domain
containing 1 (WWC1) gene could inhibit breast can-
cer progression. The gene encodes a protein called
WWC1 (or KIBRA) which interacts with PTPN14
(protein tyrosine phosphatase nonreceptor 14) and
inhibits the oncogenic activity of YAP/TAZ [6].
WW and C2 domain containing 1 consists of two
WW domains in the amino-terminus, an internal C2-
like domain, and a carboxy-terminal glutamic acid-
rich stretch. The protein was originally found to be
predominantly expressed in the kidneys and brain [7]
and is suspected to be involved in memory perfor-
mance and associated with age-dependent risk of
Alzheimer’s disease [8–11]. Studies also found that
the protein was involved in regulation of cell migra-
tion [12–14]. Genetic screening of Drosophila sug-
gests that this gene may function as a potential
tumor suppressor by regulating the Hippo signaling
pathway [15–17] which controls tissue growth and
tumorigenesis, inhibits cell proliferation, and pro-
motes apoptosis [18–23]. WWC1 associates with both
large tumor suppressor (Lats) 1 and Lats2 to regu-
late the Hippo signaling in human cells [24]. One
study indicated that activation of the Hippo signal-
ing pathway by WWC1 in breast cancer cells could
suppress epithelial-to-mesenchymal transition (EMT)
[25]. Another showed that WWC1 regulated epithe-
lial cell polarity by suppressing apical exocytosis
through direct inhibition of aPKC kinase activity in
the PAR3/PAR6/aPKC complex [26]. Loss of epithe-
lial cell polarity is intricately related to tumor pro-
gression and invasion [27]. A previous study also
found that WWC1 formed a complex with dynein
light chain 1, an estrogen receptor-a (ER)-interacting
protein, and played a role in ER transactivation in
breast cancer cells [24].
Despite the growing evidence on WWC1’s involve-
ment in breast cancer progression, no study has eval-
uated its relationship with tumor characteristics and
patient survival. To address these issues, we con-
ducted a clinical study to examine WWC1 expression
in association with patient clinical and pathological
features as well as disease outcomes.
Materials and methods
Patients and tumor samples
Breast tumor samples were collected from patients during
surgery in a university hospital between January 1998 and
July 1999 and in Mauriziano Hospital between October
1996 and August 2012. Both hospitals are affiliated with
University of Turin. The patients were followed regularly
after surgery for postoperative treatment and checkup. The
average age of patients at surgery was 58 years (range: 23–
89). The median relapse-free survival (RFS) and overall
survival (OS) were 82.2 months (range: 1.7–196.4) and
83.6 months (range: 4.2–196.4), respectively. Information
on disease stage, tumor grade, hormone receptor status,
follow-up time, and survival outcomes was extracted from
patient medical records and follow-up contacts. A detailed
description of the information has been described elsewhere
[28]. The study was approved by the ethical review commit-
tees in the hospitals, and informed written consents were
obtained from the patients. The study methodologies con-
formed to the standards set by the Declaration of Helsinki.
RNA extraction
Total RNA was extracted from 470 fresh-frozen breast
tumor samples using the AllPrep DNA/RNA Kit (Qia-
gen, Hilden, Germany). The concentrations and qualities of
RNA were measured with the NanoDrop 1000 spectropho-
tometer, and the specimens were stored at 80 °C until
analysis. The RNA integrity was assessed on the Agilent
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Quantitative reverse transcriptase PCR
WWC1 expression was analyzed in 470 tumor samples using
quantitative reverse transcriptase PCR (qRT-PCR). PCR
primers were designed and synthesized by IDT (San Diego,
CA, USA). Total RNA (1 lg) was reverse-transcribed using
the cDNA Reverse Transcription Kit (LifeTech, Carls-
bad, CA, USA); qRT-PCR was performed with the SYBR
Select Master Mix (LifeTech) in a 384-well plate using the
Roche LightCycler 480 real-time PCR detection system
(Roche Diagnostics Ltd., Rotkreuz, Switzerland). In each
PCR (10 lL), cDNA template (0.5 lL) was mixed with
200 nM primers and 5 lL SYBR PCR master mix. Cycling
conditions included the following: 50 °C for 2 min to acti-
vate UDG, 95 °C for 2 min to activate Taq polymerase, 40
cycles of 95 °C for 15 s and 60 °C for 60 s, and 60 °C for
1 min. The cycle threshold (Ct) was determined for each
sample in triplicate. WWC1 expression was normalized to
GAPDH, and the relative value was calculated as expression
index (EI), using the formula 1000 9 2(DCt), where
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DCt = Ct(WWC1)  Ct(GAPDH). PCR primers were 50-
TCCGCAGTCCTGGAAACATT-30 (forward) and 50-GTG
GATTCCCAATGAGCCGA-30 (reverse) for WWC1, and
50-GTCAAGGCTGAGAACGGGAA-30 (forward) and 50-
AAATGAGCCCCAGCCTTCTC-30 (reverse) for GAPDH.
Breast cancer microarray analysis
Of the 470 tumor samples analyzed by qRT-PCR forWWC1
expression, 204 samples were also used for microarray analy-
sis with the Illumina Expression BeadChip (HumanRef-8 v3)
(Illumina, San Diego, CA, USA) according to the manufac-
turer’s protocol, which was described elsewhere [29,30]. In
brief, microarray data were preprocessed by the BeadStudio
software and analyzed using the R statistical software and
Bioconductor [31]. The Lumi R package was used to normal-
ize the data [32]. The genefilter package was applied for non-
specific filtering; gene expression levels with interquartile
range < 0.5 were discarded.
Statistical methods
Values of WWC1 EI were categorized into three groups
according to the tertile distribution: low, medium, and
high. Chi-square test was performed to evaluate the associ-
ation between WWC1 expression and clinicopathologic
characteristics of breast cancer patients. The association of
WWC1 expression with breast cancer survival was analyzed
using the Kaplan–Meier method and log-rank test. Univari-
ate and multivariate Cox proportional hazards regression
models were used to determine the hazard ratio (HR) and
95% confidence interval (CI) between the risk of relapse or
death and WWC1 expression. In multivariate analysis, the
regression models were adjusted for age at surgery, tumor
grade, disease stage, and ER and progesterone receptor
(PR) status. To validate the association of WWC1 expres-
sion with breast cancer survival, an online tool named
Kaplan–Meier Plotter (http://kmplot.com/analysis/) was
used to analyze the relationship between breast cancer sur-
vival and WWC1 expression based on the datasets available
online [33]. Spearman’s rank correlation analysis was per-
formed to identify genes whose expression was correlated
with WWC1 using our microarray data. These WWC1-
correlated genes were interrogated by the bioinformatics
software Ingenuity Pathway Analysis (IPA), which pre-
dicted potential signaling pathways influenced by WWC1.
WWC1 methylation data generated by the Illumina
HumanMethylation450 BeadChip (HM450) in normal tis-
sue samples in The Cancer Genome Atlas (TCGA) Breast
Invasive Carcinoma Provisional Database were downloaded
from FireBrowse (http://firebrowse.org). WWC1 gene
methylation and mRNA expression (RNA Seq V2 RSEM)
data in TCGA were retrieved from the Web-based tool
cBioPortal (http://www.cbioportal.org/index.do) which only
contains methylation data from the probes that had strong
negative correlations with methylation signals [34,35]. Cor-
relations between DNA methylation and gene expression of
WWC1 were analyzed using the Spearman correlation coef-
ficient within GRAPHPAD PRISM 7 (GraphPad Software Inc.,
San Diego, CA, USA). All the statistical tests were per-
formed with the Statistical Analysis System (SAS) software,
version 9.2 (SAS Institute Inc., Cary, NC, USA). P-values
were two-sided, and those < 0.05 were considered statisti-
cally significant.
Results
Relationship between WWC1 expression and
patient characteristics
Table 1 shows the clinicopathologic characteristics of
470 breast cancer patients in association with
WWC1 expression measured by qRT-PCR. Low
expression of WWC1 was significantly associated
with advanced-stage diseases (P = 0.018) and high-
grade tumors (P < 0.0001). Patients with ER-negative
tumors had lower expression of WWC1 compared
with those with ER-positive tumors (P = 0.0017). A
similar relationship was also observed for PR
(P = 0.00029). A correlation analysis was performed
on 204 samples which had WWC1 expression data
generated by both qRT-PCR and microarray. A sig-
nificant correlation (Spearman r = 0.46, P < 0.0001)
was found between the two methods. In a TCGA
dataset, WWC1 expression was lower in breast
tumors compared to matched adjacent normal tissues
(P = 0.043; Fig. 3D).
WWC1 expression and breast cancer survival
Associations of breast cancer survival with WWC1
expression are shown in Table 2. Compared to those
with high expression, patients with low expression of
WWC1 had higher risk of relapse (HR = 1.49, 95%
CI: 1.15–1.94, P for trend = 0.0028) and higher risk of
death (HR = 1.66, 95% CI: 1.23–2.24, P for
trend = 0.00089). After adjusting for age at surgery,
tumor grade, disease stage, and ER and PR status, the
association with relapse remained significant
(HR = 1.33, 95% CI: 1.003–1.75, P for trend = 0.047).
Since the associations with survival outcomes were not
substantially different between low and medium
WWC1 expression, we grouped the two groups
together and compared their disease outcomes with
those of high WWC1 expression. Survival analysis
showed that patients with low and mid expression
(low and mid tertile) had significantly increased risk of
relapse and death (HR = 2.06, P = 0.0038, and
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HR = 2.76, P = 0.00095, respectively; Table 2,
Fig. 1A,B) compared to those with high expression
(high tertile). The association remained significant for
relapse after adjusting for clinical and pathological
variables (HR = 1.83, P = 0.024; Table 2).
The relationship between breast cancer survival
and WWC1 expression was also analyzed using an online
tool, the Kaplan–Meier Plotter, in an online database
containing 5134 breast cancer samples with a mean fol-
low-up of 69 months from 35 publically available micro-
array datasets (E-MATB-365, E-TABM-43, GSE11121,
GSE12093, GSE12276, GSE1456, GSE16391, GSE16446,
GSE16716, GSE17705, GSE17907, GSE18728,
GSE19615, GSE20194, GSE20271, GSE2034, GSE20685,
GSE20711, GSE51653, GSE2603, GSE16971, GSE2990,
GSE31448, GSE31519, GSE32646, GSE3494, GSE37946,
GSE41998, GSE42568, GSE45255, GSE4611, GSE5327,
GSE6532, GSE7390, and GSE9195). The microarray
probe 213085_s_at was used to represent WWC1
expression which was categorized into high and low
groups by upper tertile. As shown in Fig. 1C,D, high
WWC1 expression was associated with RFS (log-rank
P = 0.0043), but not with OS.
WWC1-related pathways
To explore the WWC1-related signaling pathways,
we performed co-expression analysis on genes signifi-
cantly correlated with WWC1 expression in our
breast cancer microarray data. A total of 3560 out
of 22 184 genes were found to be significantly co-
expressed with WWC1 (FDR q value < 0.05 and
Spearman correlation coefficient > 0.2). Bioinformat-
ics analysis of these genes by IPA suggested that the
top five canonical pathways involved were EIF2 sig-
naling, mTOR signaling, Hippo signaling, regulation
of eIF4 and p70S6K signaling, and tRNA charging
(Fig. 2A,B).
Table 1. Associations of WWC1 expression with clinical and pathological factors of breast cancer.
Variables
Total No.
(N = 470)
WWC1 expression
P-value
Low
No. (%)
Mid
No. (%)
High
No. (%)
Disease stage
Stage 1 151 (33.93) 39 (25.83) 50 (33.11) 62 (41.06) 0.018
Stage 2 222 (49.89) 74 (33.33) 80 (36.04) 68 (30.63)
Stages 3 and 4 72 (16.18) 31 (43.06) 18 (25.00) 23 (31.94)
Tumor grade
Grade 1 48 (10.55) 13 (27.08) 10 (20.84) 25 (52.08) < 0.0001
Grade 2 178 (39.12) 42 (23.60) 71 (39.89) 65 (36.52)
Grade 3 229 (50.33) 95 (41.48) 73 (31.88) 61 (26.64)
ER status
Positive 313 (68.19) 85 (27.16) 114 (36.42) 114 (36.42) 0.0017
Negative 146 (31.81) 64 (43.84) 42 (28.77) 40 (27.40)
PR status
Positive 171 (51.82) 43 (25.15) 65 (38.01) 63 (36.84) 0.00029
Negative 159 (48.18) 67 (42.14) 46 (28.93) 46 (28.93)
Table 2. Associations of WWC1 expression with breast cancer survival.
Variables
RFS
P-value
OS
P-value
RFSa
P-value
OSa
P-valueHR 95% CI HR 95% CI HR 95% CI HR 95% CI
High 1 1 1 1
Mid 1.88 1.09–3.24 0.024 2.53 1.31–4.87 0.0055 1.83 1.02–3.27 0.042 1.78 0.87–3.62 0.11
Low 2.30 1.33–3.99 0.0030 3.05 1.58–5.89 0.00093 1.83 1.02–3.29 0.044 1.94 0.97–3.89 0.061
Continuous 1.49 1.15–1.94 0.0028 1.66 1.23–2.24 0.00089 1.33 1.003–1.75 0.047 1.36 0.98–1.89 0.068
High
(upper tertile)
1 1 1 1
Low (lower
two tertiles)
2.06 1.26–3.37 0.0038 2.76 1.51–5.03 0.00095 1.83 1.08–3.08 0.024 1.86 0.99–3.52 0.055
The significant statistical results are indicated in bold.
aAdjusted for age at surgery, tumor grade, disease stage, ER, and PR.
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WWC1 methylation status and expression
Based on the UCSC Genome Browser, a CpG island
was identified within the WWC1 promoter region
(Fig. 3A). Eight methylation probes, cg26980033,
cg07243784, cg09547099, cg02865818, cg05253577,
cg11614065, cg15232798, and cg14599284, were
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Fig. 1. Kaplan–Meier survival curves in patients with high and low WWC1 expression. (A) RFS curves in patients of our study with high
(upper tertile) and low (two lower tertiles) expression of WWC1. (B) OS curves in patients of our study with high (upper tertile) and low
(two lower tertiles) expression of WWC1. (C) RFS curves in patients from online datasets with high (upper tertile) and low (two lower
tertiles) expression of WWC1. (D) OS in patients from online datasets with high (upper tertile) and low (two lower tertiles) expression of
WWC1.
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designed in the region by Illumina in the
HumanMethylation450 BeadChip. A significant corre-
lation between WWC1 methylation and expression
across all the probes in the gene was observed
(r = 0.29, P < 0.0001; Fig. 3B). Analyzing methyla-
tion at each specific probe in relation to gene expres-
sion in 84 breast tumor samples and matched adjacent
normal tissues, we also found that methylation in most
of the probes was inversely correlated with expression
(Fig. 3C).
Discussion
In this study, we found that WWC1 expression was
low in breast tumors compared to normal tissues and
that low expression was associated with aggressive
tumors and poor RFS. The WWC1 gene is located in
5q34 with high expression in the brain and kidneys [7].
Most studies have investigated the effect of WWC1 on
cognition and memory performance. Although its
function in non-neuronal cells is less clear, emerging
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Fig. 2. Signaling pathways identified by IPA based on the genes co-expressed with WWC1 in our expression microarray data. (A) Top 5
canonical pathways based on P-value; (B) WWC1 in the Hippo signaling pathway. Node shape represents the functional class of gene
product. Double outline for complexes/group of different proteins. Purple for upregulation.
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evidence suggests that WWC1 may play a role in can-
cer. Decreased WWC1 was shown to maintain the
stemness of osteosarcoma cells [36]. Knockdown
WWC1 expression enhanced the migration and inva-
sion of immortalized breast epithelial cells, and
reduced expression of WWC1 in claudin-low breast
cancer was associated with poor prognosis [25]. Loss
of WWC1 function could also induce EMT and pro-
mote mammary epithelial cell transformation, whereas
WWC1 overexpression was found to suppress head
and neck squamous cell carcinoma cells in forming
colony and oncosphere in soft agar [37]. Based on the
findings, WWC1 was considered a potential tumor
suppressor [38]. A recent study confirmed that WWC1
could inhibit breast tumor metastasis both in vitro and
in vivo [6].
Consistent with the above reports, we found that
low expression of WWC1 was associated with shorter
RFS, suggesting that WWC1 may play a role in the
suppression of tumor progression. The association
between WWC1 and RFS was replicated indepen-
dently in a larger dataset. Despite most studies show-
ing WWC1 as a possible tumor suppressor, a few
studies found inconsistent results. One study showed
that high expression of WWC1 was associated with
poor prognosis of gastric cancer patients with low
expression of atypical protein kinase C [39]. A recent
study reported that WWC1 could enhance cell prolifer-
ation, migration, and invasion in both immortalized
and cancerous prostate epithelial cells, and overexpres-
sion of WWC1 was observed in prostate cancer [14].
These inconsistent findings may indicate that WWC1
has tissue-specific and/or context-dependent effects on
cancer cells. More than 30 public microarray datasets
were included in the Kaplan–Meier Plotter analysis,
and these datasets had diverse patient background and
treatment, which may affect OS outcome.
WW and C2 domain containing 1 was found to reg-
ulate growth suppression through the Hippo signaling
pathway in Drosophila [15–17], and this finding was
confirmed in mammalian cells [40]. Based on our
microarray data on gene expression, we confirmed that
WWC1 was involved in the Hippo signaling pathway
in our IPA, which focused on the genes co-expressed
with WWC1. We also found that these co-expressed
genes were enriched in the mTOR signaling pathway.
Hippo and mTOR are two critical pathways that con-
trol cell growth and tissue/organ homeostasis. Previous
studies have provided evidence for signaling cross talk
between the mTOR and Hippo pathways. YAP, which
is the main downstream target of the mammalian
Hippo pathway, can regulate the mTOR pathway via
its effects on miR-29 expression [41]. WWC1 could be
an important signaling node linking mTOR and Hippo
pathways. Promoter methylation that leads to tumor
suppressor gene silencing is an important mechanism
involved in tumor initiation, progression, and metasta-
sis [42,43]. WWC1 methylation was found to be associ-
ated with unfavorable prognostic indicators in patients
with chronic lymphocytic leukemia [44]. Epigenetic
inactivation of WWC1 was found frequently in B-cell
acute lymphocytic leukemia [45]. One study reported
that WWC1 expression was significantly affected by
CpG island methylation in the promoter region and
the promoter methylation was elevated in human clear
renal cell carcinoma [46]. In our study, we found a sig-
nificant inverse correlation between CpG methylation
and WWC1 expression, suggesting that DNA methyla-
tion may regulate WWC1 expression. We also noticed
in our study that methylation regulation was not
restricted to the promoter region as methylation of
CpG sites in other regions of the gene could be
involved (data not shown).
Genetic polymorphisms in the WWC1 gene may
affect expression and contribute to disease risk. One
recent study identified WWC1 as a possible genetic
locus for breast cancer susceptibility among women of
African ancestry [47]. A genomewide association study
reported that individuals carrying the T allele of
rs17070145 in WWC1 had significantly better memory
scores in the Buschke Selective Reminding Test com-
pared to those carrying the C allele [9]. The single
nucleotide polymorphism rs17070145 resides in intron
9 of the WWC1 gene. We found that patients with
genotype TT or TC in rs17070145 had better relapse-
free and OS compared to those with genotype CC, but
eQTL was not detected in this locus, indicating no
impact of this genotype on WWC1 expression (data
not shown). The biological mechanism underlying the
genotype’s association with breast cancer survival
remains to be elucidated.
Of note, the relatively small sample size may limit the
statistical power of our study. We also did not evaluate
whether our tumor samples had a deletion in chromo-
some 5q which may explain low expression ofWWC1.
Conclusions
In summary, we found that low WWC1 expression
was associated with shorter RFS of breast cancer
patients compared to high expression and that the
association was independent from tumor grade, disease
stage, and hormone receptor status. We further repli-
cated this association in a large independent dataset
available online. The study also showed that WWC1
expression was inversely associated with tumor grade
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and disease stage and hormone receptor-positive
tumors had higher expression than receptor-negative
ones. These associations indicate that tumor biology
and cell differentiation may influence the expression of
WWC1. Bioinformatics analysis of our microarray
data on gene expression confirmed that WWC1 expres-
sion was involved in the Hippo signaling pathway.
Analysis of online methylation data indicated that
DNA methylation could influence WWC1 expression.
Further investigating the biological actions of WWC1
in breast cancer will help to elucidate the mechanisms
of tumor progression.
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